1. Introduction {#sec1}
===============

Folliculogenesis is a complex and precisely regulated process essential for human reproduction. During growth and maturation of the ovarian follicle, granulosa cells divide and differentiate into a multilayer of Mural Granulosa Cells (MGCs) that line the follicular compartment and a cluster of Cumulus Cells (CCs) that tightly surround the oocyte \[[@r1]\]. Even though these two cell types have a common progenitor in the primordial follicle, their differentiation during folliculogenesis results in cells with specific functions and gene expression profiles \[[@r2], [@r3]\]. More precisely, CCs are specialized in nutritional support and trafficking of macromolecules \[[@r2], [@r4]\] while MGCs support the oocyte *via* endocrine and paracrine pathways \[[@r5]\].

MicroRNAs (miRNAs) are small non-coding RNAs that modulate gene expression through inhibition of protein translation and/or reducing mRNA stability. MiRNAs have been shown to regulate a wide variety of cellular processes \[[@r6]\]. Several protein-coding genes are differentially expressed between CCs and MGCs and their relevance for CC and MGC function has been previously demonstrated in the context of cell communication, extracellular matrix and signaling pathways \[[@r2], [@r7]\]. In contrast, the expression and function of miRNAs in CCs and MGCs are only scarcely investigated \[[@r8], [@r9]\]. Therefore, we aimed to determine the miRNA profile in CCs and MGCs and to identify differentially regulated miRNAs between these specialized cell types.

2. Materials and Methods {#sec2}
========================

2.1. Patients and Cell Culture {#sec2.1}
------------------------------

Primary Granulosa Cells (PrGCs) were obtained from pre-ovulatory follicles from seven individual healthy women between 24-38 years old undergoing ovum pick-up for *in vitro* fertilization (IVF) for male factor infertility at the University Medical Centre Groningen, The Netherlands. Patients received human menopausal gonadotrophin 150-225 IU per day (Menopur^®^, Ferring Pharmaceuticals, The Netherlands) and a daily subcutaneous GnRH analog, triporeline 0.5 mg (Decapeptyl^®^, Ferring Pharmaceuticals, The Netherlands). Oocytes were collected 36 hours after treatment with 5000 IU human chorionic gonadotropin (hCG) (Pregnyl^®^ Organon, Oss, The Netherlands) and cumulus aggregates were obtained by visual inspection and manual separation from the cumulus-oocyte complex followed by centrifugation in HBSS (Life technologies, USA) for 10 minutes at 400g. For MGCs isolation, the Follicular Fluid (FF) was centrifuged 5 minutes at 400g and 5 minutes at 500g, and the pellet was resuspended in HBSS. Blood cells were separated from the MGCs using a 40% Percoll^TM^ (GE Healthcare, Sweden) gradient and 10 minutes centrifugation at 550g. Cells from the interface were collected and washed in HBSS through 10 minutes centrifugation at 450g. For both CCs and MGCs the pelleted cells were resuspended in 1 ml trypsin followed by 3-4 minutes incubation at 37°C to disperse the clustered cells. CCs and MGCs from individual patients were cultured in DMEM/F12 medium supplemented with 10% FCS, 1% penicillin-streptomycin-amphotericin B at 37°C and 5% CO2 or directly harvested. Cultured cells were washed with HBSS every two days until the culture was devoid of contaminants upon visual inspection. For the MGCs/CCs sequencing and RT-qPCR validation experiments, cultured cells (2-4 days) were washed 2x with HBSS and incubated for 24 hours with serum-free DMEM/F12 supplemented with 1% penicillin-streptomycin-amphotericin-B and 10 uM androstenedione (AST) (Sigma, USA). Three patients were randomly selected for small RNA sequencing analysis and all seven were used for RT-qPCR experiments. From an additional three patients MGCs and CCs were directly harvested after isolation to compare the possible effect of short-term culturing on the miRNA expression of MGCs and CCs.

2.2. RNA Isolation and Quality Control {#sec2.2}
--------------------------------------

RNA was isolated using the miRNeasy micro kit (QIAGEN, Germany) according to the manufacturer's instructions. For sequencing samples, RNA quality was assessed using Experion™ RNA StdSens Analysis Kit (Bio-Rad, USA).

2.3. Small RNA Sequencing {#sec2.3}
-------------------------

Small RNA libraries were generated from 200 ng total RNA using NEXTflex Small RNA Sequencing Kit v3 for Illumina Platforms (Bio Scientific, Austin, TX, USA). Libraries were purified with an automated agarose gel separation system (Labchip XT, PerkinElmer, Waltham, MA, USA) and sequenced on Illumina Nextseq500 (Illumina, San Diego, CA) using default parameters (single read 1x50bp). Briefly, 3′- and 5′-adaptor sequences were removed using the CLC Genomics Workbench (CLC Bio, Cambridge, MA). RNA reads were analyzed with miRDeep version 2.0 \[[@r10]\] and annotated against miRBASE version 21 (<http://www.mirbase.org>) allowing one mismatch. Total read counts were standardized to read counts per million (RPM). Read counts for miRNAs with the same mature sequence were merged. For statistical analysis, we included all unique miRNAs with an average read count of at least 20 in at least one out of the two cell types. Small RNA sequencing data are available at the Gene Expression Omnibus data repository, accession number GSE106776.

2.4. Reverse Transcriptase (RT)-Quantitative (q)PCR {#sec2.4}
---------------------------------------------------

RT-qPCR was performed using TaqMan miRNA quantitative PCR assays (Thermo Fisher Scientific Inc., USA). Per miRNA the most abundant mature miRNA isoform was identified from the small RNA sequencing data and used to select a pre- or custom- designed taqman assay (Supplementary Table **1**). cDNA synthesis was performed in a multiplex reaction as described previously \[[@r11]\]. Expression levels were normalized to RNU44. Cycle threshold (Ct) values were determined with the QuantStudio RT-PCR software version 1.2 (Applied Biosystems, USA). Relative expression levels of miRNAs were determined by using the 2^−ΔCt^ method \[[@r12]\].

2.5. Proven miRNA Target Gene Interactions and Gene Ontology Analysis {#sec2.5}
---------------------------------------------------------------------

Proven target genes of the validated miRNAs were retrieved from the miRTarBase database (<http://mirtarbase.> mbc.nctu.edu.tw/, release 7.0, Sept 15^th^, 2017). We only included genes that were validated with at least a reporter assay based method. Gene ontology analysis was performed with DAVID 6.8 bioinformatic database (<https://david.> ncifcrf.gov/) using an FDR cut-off of 0.001.

2.6. Statistical Analysis {#sec2.6}
-------------------------

For sequencing data, a paired t-test was used to analyze differential expression of individual miRNAs in MGC and CCs, considering p\<0.05 as statistically significant, using GeneSpring GX software version 12.5 (Agilent Technologies, Santa Clara, CA). For the RT-qPCR validation, one-tailed paired t-test was used (GraphPad Prism 5.00 software). The heatmap was generated with Genesis software \[[@r13]\] and the hierarchical clustering was shown with median centering of the genes and Pearson correlation.

2.7. Institutional Review Board Approval {#sec2.7}
----------------------------------------

Institutional Review Board (IRB) approval was requested but waived, since in this study only anonymized material and data were used from patients who had signed the universal consent form for the anonymous usage of their data and who did not object to the usage of the waste material.

3. Results {#sec3}
==========

Small RNA sequencing was performed to establish the miRNA expression profile of MGCs and CCs. A comparison of the ten most abundantly expressed miRNAs in MGCs and CCs revealed that the majority of highly abundant miRNAs are shared between the two cell types with the highest expression levels for miR-21-5p, let-7a-5p and let-7f-5p (Fig. **[1](#F1){ref-type="fig"}**). MiR-30a-5p was uniquely present in the top-10 most abundantly expressed miRNAs of MGCs, while miR-320a was only present in the top-10 of CCs. Principal component analysis showed that 43% of the variation in miRNA expression within the MGCs and CCs could be explained by differences between cell types (first component) and 21% by differences between patients (second component). In total, 53 miRNAs were significantly differentially expressed between MGCs and CCs. Of those 12 showed higher expression levels in MGCs while 41 were more abundant in CCs (Fig. **[2](#F2){ref-type="fig"}**).

To confirm the small RNA sequencing results, we selected the five miRNAs with the highest fold change and a read count of 500 rpm or more in MGCs or CCs for RT-qPCR analysis (Table **[1](#T1){ref-type="table"}**). Four of the selected candidates were increased in CC, *i.e*. miR-183-5p, miR-182-5p, miR-509-3p and miR-149-5p, while miR-146a-5p was increased in MGC. Validation of the differential expression patterns was performed on the same samples as used for small RNA sequencing (n=3 individual patients) as well as in an independent set of samples (n=4 individual patients). RT-qPCR analysis confirmed the expected significant differences for four out of five miRNAs (Fig. **[3](#F3){ref-type="fig"}**). For the fifth miRNA, *i.e.* miR-183-5p, no expression in MGCs or CCs was detected by RT-qPCR. To determine the possible effect of short-term culturing, miRNA levels were also studied in directly isolated MGCs and CCs (n=3). This revealed similar differences in miRNA expression as compared to the RT-qPCR and RNA-seq results using cultured cells (Fig. **S1**).

To obtain insight into the possible functions of the four validated miRNAs we retrieved known targets using miRTarBase \[[@r14]\]. This resulted in the identification of 91 genes in total without any overlap between the genes targeted per miRNA. 37 targets were identified for miR-146a-5p, 43 for miR-182-5p, 2 for miR-509-3p and 9 for miR-149-5p. Gene Ontology (GO) analysis revealed 12 enriched GO terms for miR-146a-5p and 10 for miR-182-5p (Table **[2](#T2){ref-type="table"}**). No significantly enriched GO terms were found for miR-509-3p and miR-149-5p. The GO term for Ubiquitin-Like Protein (UBL) conjugation was enriched within miR-146a-5p as well as miR-182-5p proven target genes. Next, we performed GO analysis using the combined targets of the three miRNAs with increased abundance in CCs, *i.e.* miR-182-5p, miR-509-3p and miR-149-5p (54 target genes). This revealed 15 significantly enriched GO terms, including increased significance for UBL conjugation and regulation of transcription.

4. Discussion {#sec4}
=============

Although MGCs and CCs are closely related cell types, clear differences in their functions and protein coding gene expression profiles have been described \[[@r2], [@r3]\]. In our study, we determined the miRNA expression profile of human MGCs and CCs using small RNA sequencing. Although the majority of the highly abundant miRNAs showed similar expression levels in both cell types, we were able to identify 53 significantly differentially expressed miRNAs and validated 4 of them using RT-qPCR. Identification of differentially expressed miRNAs is a first step to elucidate the potential contribution of miRNAs in granulosa cell function and cell type specialization of MGCs and CCs.

Velthut *et al*., previously described the differential expression of miRNAs in MGCs and CCs. We found nine significantly differentially expressed miRNAs in common with their study (upregulated in MGC: hsa-miR-146a-5p, hsa-miR-10b-5p, hsa-miR-29b-3p and hsa-miR-142-5p and upregulated in CC: hsa-let-7c-5p, hsa-miR-125b-5p, hsa-miR-1275, hsa-miR-129-5p and hsa-miR-129-2-3p). A large proportion of the previously identified differentially expressed miRNAs (50%) showed in our study less than 20 RPM in both groups. This suggests that these miRNAs are expressed at a relatively low level and that these are possibly of minor relevance to MGC and CC biology. The limited overlap between the two studies might be related to differences in experimental procedures and the data analysis strategy. We used short-term cultured MGCs and CCs, while Velthut *et al.* used directly isolated cells. However, for the four selected miRNAs, we observed similar expression patterns in cultured and non-cultured MGCs and CCs (Fig. **S1**). Both current studies used MGCs and CCs from patients treated with gonadotropins. To exclude possible influences of this treatment on the miRNA expression profile it would be interesting to define the miRNA profile of MGCs and CCs from patients with physiological ovarian cycles without gonadotropin treatment in future studies.

Several of the significantly differentially expressed miRNAs have been implicated to positively or negatively affect steroidogenesis. For example, miR-149-5p inhibits estradiol release \[[@r8]\] and miR-509-3p promotes estradiol secretion by targeting MAP3K8 \[[@r15]\]. Moreover, miR-183-5p was described to inhibit the progesterone release \[[@r8]\]. For other miRNAs a role in regulating apoptosis and proliferation in PrGC has been reported, with miR-146a-5p promoting apoptosis of MGCs by directly targeting IRAK1 and TRAF6 \[[@r16]\] and miR-503-5p inhibiting proliferation by targeting CCND2 \[[@r17]\].

Analysis of previously validated targets for the four differentially expressed miRNAs revealed a total of 91 targets. GO analysis using this list of targets revealed 12 enriched GO terms for miR-146a-5p and 10 for miR-182-5p. One GO term, UBL conjugation, was shared between these two miRNAs. This term was even more enriched when targets of miR-149-5p, miR-182-5p and miR-509-3p (all miRNAs that were higher expressed in CCs) were combined in the GO analysis. Another term for which the significance increased in the combined analysis was positive regulation of transcription, indicating that genes related to this term and UBL conjugation are targeted by multiple miRNAs expressed at higher levels in CCs. In future studies, it would be interesting to further focus on the role of these miRNAs in MGCs and CCs in relation to the specific functions of these cells.

Conclusion
==========

We have defined the miRNA profiles of MGCs and CCs and identified 53 differentially expressed miRNAs between these specialized cell types. Further studies may build on our data to elucidate the functions of these miRNAs in relation to folliculogenesis and their impact on oocyte quality.
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![RT-qPCR validation of differentially expressed miRNAs between MGCs and CCs as identified by small RNA sequencing. Closed circles represent the three patients used for small RNA sequencing and open circles represent four additional patients. n= 7 individual patients in total. \*\* p \<0.01, \*\*\* p \< 0.001.](MIRNA-8-61_F3){#F3}

###### 

Overview of all miRNAs differentially expressed between mural (MGCs) and cumulus (CCs) granulosa cells with \>500 RPM in at least one of the two cell types.

  **miRNA**             **Read Counts (RPM)\***   **FC**   **p-value**   
  --------------------- ------------------------- -------- ------------- -------
  *Increased in CCs*                                                     
  **hsa-miR-183-5p**    535                       53       10.1          0.013
  **hsa-miR-182-5p**    1123                      159      7.1           0.021
  **hsa-miR-509-3p**    1266                      254      5.0           0.013
  **hsa-miR-149-5p**    961                       204      4.7           0.001
  hsa-miR-513a-5p       717                       153      4.7           0.002
  hsa-let-7c-5p         18366                     7628     2.4           0.017
  hsa-miR-342-3p        820                       348      2.4           0.039
  hsa-miR-23b-3p        10957                     4881     2.2           0.031
  hsa-miR-574-5p        1739                      811      2.1           0.005
  hsa-miR-15b-5p        4059                      2276     1.8           0.023
  hsa-miR-365a-3p       1643                      956      1.7           0.008
  hsa-miR-339-5p        516                       308      1.7           0.046
  hsa-miR-27b-3p        8550                      5132     1.7           0.045
  hsa-miR-505-3p        569                       355      1.6           0.005
  **miRNA**             **Read Counts (RPM)\***   **FC**   **p-value**   
  **CCs**               **MGCs**                                         
  hsa-miR-503-5p        1062                      664      1.6           0.011
  hsa-miR-128-3p        2734                      1746     1.6           0.007
  hsa-miR-92a-3p        20973                     14469    1.4           0.030
  hsa-miR-361-5p        2869                      1987     1.4           0.005
  hsa-let-7a-3p         504                       358      1.4           0.011
  hsa-miR-125b-5p       4482                      3297     1.4           0.011
  *Increased in MGCs*                                                    
  **hsa-miR-146a-5p**   48                        608      12.6          0.002
  hsa-miR-675-5p        527                       921      1.7           0.006
  hsa-miR-195-5p        426                       663      1.6           0.019
  hsa-miR-27a-3p        652                       985      1.5           0.004

\* Read counts is given as the geometric mean of the RPM values across all samples. miRNAs in bold are selected for RT-qPCR validation.

###### 

Gene Ontology (GO) analysis for miR-146a-5p, miR-149-5p, miR-509-3p and miR-182-5p.

  **miR-146a-5p (up in MGCs)**                                           **GO Term**        **\# genes**   **FDR**
  ---------------------------------------------------------------------- ------------------ -------------- ----------
  Pathways in cancer                                                     15                 3.77E-07       
  Mutagenesis site                                                       20                 8.54E-07       
  Cellular response to mechanical stimulus                               7                  1.04E-05       
  Toll-like receptor signalling pathway                                  9                  1.62E-05       
  Inflammatory response                                                  10                 8.93E-05       
  Positive regulation of smooth muscle cell proliferation                6                  2.26E-04       
  Chagas disease (American trypanosomiasis)                              8                  3.27E-04       
  Ubl conjugation                                                        15                 5.26E-04       
  Lipopolysaccharide-mediated signaling pathway                          5                  8.39E-04       
  Leishmaniasis                                                          7                  6.68E-04       
  Protein binding                                                        33                 7.99E-04       
  Toxoplasmosis                                                          8                  7.77E-04       
  **miR-182-5p (up in CCs)**                                             Tumor suppressor   9              2.20E-06
  Ubl conjugation                                                        18                 9.56E-06       
  Nucleus                                                                29                 1.18E-05       
  Positive regulation of transcription, DNA-templated                    12                 4.28E-05       
  Sequence-specific DNA binding                                          12                 3.36E-05       
  Prostate cancer                                                        8                  4.66E-05       
  Negative regulation of apoptotic process                               11                 1.57E-04       
  Nucleoplasm                                                            21                 5.40E-04       
  PI3K-Akt signaling pathway                                             11                 5.67E-04       
  Cellular response to DNA damage stimulus                               8                  9.77E-04       
  **miR-182-5p, miR-509-3p, miR-149-5p (all up in CCs)**                 Ubl conjugation    23             3.91E-08
  Positive regulation of transcription, DNA-templated                    15                 5.22E-07       
  Sequence-specific DNA binding                                          14                 4.81E-06       
  Tumor suppressor                                                       9                  1.65E-05       
  Prostate cancer                                                        9                  1.69E-05       
  Nucleus                                                                33                 4.97E-05       
  Negative regulation of apoptotic process                               12                 1.79E-04       
  PI3K-Akt signaling pathway                                             13                 1.40E-04       
  Positive regulation of transcription from RNA polymerase II promoter   16                 2.59E-04       
  Cellular response to DNA damage stimulus                               9                  3.59E-04       
  Phosphoprotein                                                         40                 3.83E-04       
  Transcription regulation                                               21                 4.57E-04       
  Pathways in cancer                                                     13                 5.79E-04       
  Transcription                                                          21                 7.17E-04       
  Activator                                                              12                 7.44E-04       

FDR= false discovery rate
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